← Back to Patent Explorer
US4847281A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of medical treatment of addiction

Assignee: Glaxo Group Ltd
•
Filing: 1987-11-20
•
Granted: 1989-07-11
•
Expires: 2007-11-20
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H</ U>-carbazol-4-one and physiologically acceptable salts and solvates thereof in the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or susbtances of abuse.

Inventors

  • 👤 Michael B. Tyers

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 05:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/435; A61K31/46; A61P; A61P39/00; A61P39/02

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 76 words
A method of treatment for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance or abuse and/or for the suppression of dependence on drugs or substances of abuse, which comprises administering to a human or animal subject suffering from or liable to suffer from said withdrawal syndrome and/or dependent on a drug or substance of abuse an effective amount of 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 2
Independent Claim 76 words
A method of treatment for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance or abuse and/or for the suppression of dependence on drugs or substances of abuse, which comprises administering to a human or animal subject suffering from or liable to suffer from said withdrawal syndrome and/or dependent on a drug or substance of abuse an effective amount of 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 3
Dependent Claim 19 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[m2-ethyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of the hydrochloride dihydrate salt.
Claim 4
Dependent Claim 44 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof is administered in a dose of 0.05 to 20 mg from 1 to 4 times per day, the dose being expressed as the weight of free base.
Claim 5
Dependent Claim 22 words
A method according to claim 3 wherein said dose is from 0.1 to 10 mg from 1 to 4 times per day.
Claim 6
Dependent Claim 16 words
A method according to claim 1 wherein said drug or substance of abuse is an opiate.
Claim 7
Dependent Claim 15 words
A method according to claim 1 wherein said drug or substance of abuse is cocaine.
Claim 8
Dependent Claim 16 words
A method according to claim 1 wherein said drug or substance of abuse is a benzodiazepine.
Claim 9
Dependent Claim 15 words
A method according to claim 1 wherein said drug or substance of abuse is alcohol.
Claim 10
Dependent Claim 15 words
A method according to claim 1 wherein said drug or substance of abuse is nicotine.
Claim 11
Dependent Claim 20 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered orally, buccally, parenterally, rectally, or as a depot preparation.
Claim 12
Dependent Claim 17 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of a hydrochloride.

References Cited (Backward Citations)

WO1985002115A1 Cited
GB2153821A Cited
US4721720A Cited
US4721720B1 Cited
US4753789A Cited
GB2193633A Cited
EP0272052A1 Cited
GB2206788A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-07-10 1993-01-09 1993-07-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-07-10 1997-01-09 1997-07-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-07-10 2001-01-09 2001-07-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag